

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Kevin K. Liu, et al

APPLICATION NO.: To be assigned

Examiner: To be assigned

FILING DATE:

Concurrently herewith

Group Art Unit: To be assigned

TITLE: GLUCOCORTICOID RECEPTOR

MODULATORS

Hon. Commissioner for Patents Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Martha A. Gammill

Attorney for Applicant(s)

Reg. No. 31,820

Pfizer Inc.

Patent Department, MS 4159

Eastern Point Road

Groton, Connecticut 06340

(860) 441-5940

INFORMATION DISCLOSURE STATEMENT, 9/99, (1/1)

Express Mail No. EL911724821US